No Data
No Data
No Data
Cube Pharmaceuticals (003020.SZ): Onsite inspection of methylphenidate hydrochloride extended-release tablets was completed in April 2024, and approval results are expected in 2025
Gelonghui May 24 | Cube Pharmaceutical (003020.SZ) was surveyed by investors on May 23, 2024, on “The situation of methylphenidate hydrochloride extended-release tablets?” The company replied that methylphenidate hydrochloride sustained-release tablets are three-layer osmosis pump sustained-release tablets. The application was accepted in the fourth quarter of last year, on-site inspection was completed in April 2024, and approval results are expected in 2025.
Cube Pharmaceuticals (003020.SZ): Ketone Tongluo capsules are currently mainly sold in medical institutions, and there are few retail channels
On May 24, Ge Longhui | Cube Pharmaceutical (003020.SZ) was surveyed by investors on May 23, 2024, on “The status of ketone access capsules?” The company replied that currently it is mainly sold in medical institutions, and there are few retail channels, and there is still a lot of room for improvement in hospital coverage.
Cube Pharmaceuticals (003020.SZ): Sales volume of nifedipine controlled-release tablets increased significantly after collection in countries that won the bid
Gelonghui May 24 | Cube Pharmaceuticals (003020.SZ) was surveyed by investors on May 23, 2024, on “the status of controlled release nifedipine tablets?” The company replied that the sales volume of nifedipine controlled-release tablets increased significantly after collection in the country that won the bid, and fixed costs were better shared.
Cube Pharmaceuticals (003020.SZ): Opioid analgesics have more room for future growth
Gelonghui May 24 | Cube Pharmaceutical (003020.SZ) was surveyed by investors on May 23, 2024, on “The situation of oxycodone hydrochloride sustained-release tablets?” The company replied that there is a lot of room for future growth in opioid analgesics. Among them, oxycodone hydrochloride is used in a relatively high proportion of oral medications for cancer pain. After the company launched oxycodone hydrochloride sustained-release tablets in 2023, it was mainly development and admission work, focusing on the development of key hospitals.
Further Upside For Hefei Lifeon Pharmaceutical Co., Ltd. (SZSE:003020) Shares Could Introduce Price Risks After 25% Bounce
Lifeon Pharmaceutical's Unit Gets Marketing Authorization for Loxoprofen Sodium Oral Solution
No Data